Baxter International (BAX) came out with quarterly earnings of $0.59 per share, missing the Zacks Consensus Estimate of $0.6 per share. This compares to earnings of $0.68 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -1.67%. A quarter ago, it was expected that this drug and medical device maker would post earnings of $0.48 per share when it actually produced earnings of $0.55, delivering a surprise of +14.58%.Over the last f ...

Key Takeaways BAX Q2 revenues rose 4.3% to $2.81B but missed estimates; EPS of $0.59 missed consensus mark.BAX gross margin fell 170bps to 40.7%, pressured by product mix; operating margin rose 180bps to 15.1%.BAX cut 2025 EPS guidance to $2.42-$2.52 from $2.47$2.55, citing demand softness in key categories.Baxter International Inc. (BAX) reported second-quarter 2025 adjusted earnings per share (EPS) of 59 cents, which missed the Zacks Consensus Estimate of 60 cents by 1.7%. The bottom line improved 28.3% f ...

Baxter International (BAX) Q2 2025 Earnings Call July 31, 2025 08:30 AM ET Company ParticipantsClare Trachtman - SVP & Chief Investor Relations OfficerBrent Shafer - Interim CEO & ChairmanHeather Knight - EVP & COOJoel Grade - Executive VP & CFODavid Roman - Managing DirectorTravis Steed - MD - Equity ResearchVijay Kumar - Senior MDConference Call ParticipantsRobert Marcus - Senior AnalystLawrence Biegelsen - Senior Medical Device Equity Research AnalystMatt Miksic - Equity Research AnalystOperatorGood morn ...

Baxter International (BAX) Q2 2025 Earnings Call July 31, 2025 08:30 AM ET Speaker0Good morning, ladies and gentlemen, and welcome to Baxter International Second Quarter twenty twenty five Earnings Call. Your lines will remain in a listen only mode until the question and answer segment of today's call. Star one on your touch tone phone. Once again, star and the number one. And as a reminder, this call is being recorded by Baxter and is copyrighted material.It cannot be recorded or rebroadcast without Baxter ...

Q2 2025 Performance Summary - Worldwide sales from continuing operations grew 4% on a reported basis and 1% on an operational basis[18] - Adjusted earnings per share from continuing operations totaled $0.59 per diluted share, increasing 28% as compared to the prior year period[18] - Gross Margin was 353%, with a year-over-year change of (300 bps)[20] - Operating Margin was 68%, with a year-over-year change of +20 bps[20] - Diluted EPS was $024, with a year-over-year change of +26%[20] H1 2025 Performance Summary - Sales were $54 billion, with a +5% Reported and +3% Operational[20] - Gross Margin was 341%, with a year-over-year change of (430 bps)[20] - Operating Margin was 46%, with a year-over-year change of (110 bps)[20] - Diluted EPS was $036, with a year-over-year change of +80%[20] - Adjusted Diluted EPS was $115, with a year-over-year change of +40%[20] Q3 & FY 2025 Outlook - Third-Quarter 2025 Sales Growth Reported (Continuing Operations) Guidance is 6% - 7%[60] - Third-Quarter 2025 Operational Sales Growth (Continuing Operations) Guidance is ~ 3% - 4%[60] - Third-Quarter 2025 Adjusted Diluted EPS Continuing Operations is $058 - $062[60] - Full-Year 2025 Sales Growth Reported (Continuing Operations) Guidance is 6% - 7%[62] - Full-Year 2025 Operational Sales Growth (Continuing Operations) Guidance is 3% - 4%[62] - Full-Year 2025 Adjusted Diluted EPS Continuing Operations is $242 - $252[62]

Exhibit 99.1 FOR IMMEDIATE RELEASE BAXTER REPORTS SECOND-QUARTER 2025 RESULTS DEERFIELD, Ill., JULY 31, 2025 – Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the second quarter of 2025. "For the second quarter of 2025, Baxter delivered performance in line with guidance while our employees across the globe continued advancing the company's life-sustaining Mission and building on its vision to redefine healthcare delivery," said Brent Shafer, chair and interim CEO. " ...

Core Viewpoint - Baxter International Inc. is set to announce its second-quarter 2025 results on July 31, with expectations of moderate growth despite a projected decline in revenues and earnings compared to the previous year [1][2][3]. Q2 Estimates - The consensus estimate for revenues is $2.82 billion, reflecting a 26.1% decline from the prior year's quarter [2]. - The consensus estimate for earnings is 60 cents per share, indicating an 11.8% year-over-year decline [2]. - The model estimates total revenues from continuing operations to improve by 1.3% at constant currency to $2.81 billion, with adjusted earnings per share expected to decline 11.4% to 60 cents [2]. Important Factors to Note - Baxter is anticipated to report moderate growth supported by strong execution across core segments and easing operational challenges [3]. - Sales from continuing operations grew 5% in the first quarter, driven by the Medical Products & Therapies and Healthcare Systems & Technologies segments [3]. - For Q2, the company expects reported sales growth of approximately 4% to 5% and operational growth in the 1% to 2% range [3]. Margin Profile - Baxter's adjusted operating margin improved by 260 basis points year-over-year to 14.9%, aided by strong top-line delivery and lower SG&A expenses [4]. - The margin stability is expected to continue due to operational efficiencies and ongoing cost containment initiatives [4]. Operational Performance - The completion of Baxter's transformation strategy, including the spin-offs of the Kidney Care and BioPharma Solutions businesses, has streamlined its portfolio [5]. - Management expects adjusted earnings per share in the range of 59 to 63 cents, building on the 55 cents reported in the previous quarter [5]. Recovery from Hurricane Helene - Manufacturing at the North Cove facility has returned to pre-hurricane levels, allowing for inventory replenishment and reduced product allocations [6]. - The company anticipates normalized ordering patterns as IV solution product allocations are removed [6]. Segmental Overview - The Medical Products & Therapies segment reported a 6% operational growth in Q1, with sales reaching $1.3 billion, driven by the U.S. infusion systems portfolio [7][9]. - The Healthcare Systems & Technologies segment also saw a 6% operational increase in Q1, with sales totaling $704 million, led by the Care and Connectivity Solutions division [10]. - The Pharmaceuticals segment reported 3% operational growth in Q1, with sales of $581 million, primarily driven by specialty injectables [11]. Other Sales and Revenue Streams - Other sales totaled $15 million in Q1, with drug compounding business growing 2% [12]. - MSA revenue from Vantive was reported at $63 million in Q1, with expectations of around $80 million for Q2 [12].

美国食品药品监督管理局（FDA）：截至6月27日，百特公司（BAXTER ）已报告79人因输液泵问题严 重受伤，2人死亡。 ...

Investment Rating - The report maintains a "Buy" rating for Boston Scientific (BSX), Edwards Lifesciences (EW), GE Healthcare (GEHC), Intuitive Surgical (ISRG), and Haemonetics (HAE), while downgrading Tandem Diabetes (TNDM) to "Sell/High Risk" from "Neutral/High Risk" [1][5][20]. Core Insights - The MedTech sector has shown resilience against healthcare headwinds, with a focus on returning to fundamentals and several catalysts expected to drive momentum in the second half of 2025 [1][9]. - The S&P Equipment and Supplies Index has outperformed the broader market, with a year-to-date increase of 7.2%, while relative P/E multiples remain below historical averages [2][12]. - Key upcoming catalysts include product launches and data readouts from various companies, which are anticipated to influence stock performance positively [3][10][11]. Summary by Sections Market Overview - The MedTech industry has largely absorbed tariff impacts, with a weakening USD providing additional support [1][9]. - The S&P 500 is up 6.2% year-to-date, while the S&P Equipment and Supplies Index has increased by 7.2% [2][12]. Company-Specific Insights - Boston Scientific (BSX) is expected to benefit from Farapulse and new product launches, projecting a revenue increase of 80.1% year-over-year in 2Q25 [3][10]. - Edwards Lifesciences (EW) anticipates pivotal data releases and the reopening of TAVR NCD, which could enhance its market position [3][10]. - Intuitive Surgical (ISRG) plans a broad launch of its DV5 system, which is expected to drive stock performance [4][10]. - Haemonetics (HAE) has been upgraded to "Buy" due to improved guidance and revenue growth expectations [5][20]. - Tandem Diabetes (TNDM) faces competitive pressures, leading to its downgrade to "Sell/High Risk" [5][20]. Valuation and Target Prices - Target prices have been adjusted for several companies, with BSX at $125, EW at $95, GEHC at $86, and ISRG at $650 [20][21]. - The report highlights that the relative P/E multiple for the MedTech sector is currently at 1.14x, below historical averages, indicating potential undervaluation [2][12][14].

Group 1 - Baxter International Inc. announced the appointment of Andrew Hider as President and CEO, effective no later than September 3, 2025 [1] - Brent Shafer, who has served as Chairman and interim CEO since February 2025, will transition to the role of independent Chairman of the Board [1] Group 2 - Andrew Hider has 25 years of cross-industry experience and a global perspective, focusing on growth-oriented and people-centric leadership [2] - Hider served as CEO and Director of ATS, a leading automation solutions provider, where he significantly improved profit margins and nearly doubled adjusted revenue over five years with a compound annual growth rate (CAGR) in the low double digits [4][5] - Under Hider's leadership, ATS's stock price more than doubled since 2017, outperforming major indices [5] Group 3 - Baxter International, founded in 1931 and headquartered in Deerfield, Illinois, specializes in medical products for chronic and critical care, developing and selling products for complex conditions such as hemophilia and cancer [6] - Baxter's diverse business integrates medical devices, pharmaceuticals, and biotechnology, with a leading position in home kidney therapy and recombinant factor products for bleeding disorders [6] - The company employs approximately 38,000 members globally [6]